Molecular genetics of intellectual disability by Bessa, C. et al.
7 
Molecular Genetics of Intellectual Disability 
C. Bessa, F. Lopes and P. Maciel  
Life and Health Sciences Research Institute (ICVS), School of Health Sciences,  
University of Minho, Braga, 
ICVS/3B’s - PT Government Associate Laboratory, Braga/Guimarães, 
 Portugal 
1. Introduction  
The goal of this chapter is to review the current knowledge of the genetic causes of 
intellectual disability, focusing on alterations at the chromosomal and single gene level, with 
particular mention to the new technological developments, including array technologies and 
next-generation sequencing, which allowed an enormous increase in yield from genetic 
studies. The cellular and physiological pathways that seem to be most affected in intellectual 
disability will also be addressed. Finally, a brief analysis of the contribution of the 
genetically modified animal models for the study of the pathogenesis of intellectual 
disability and for the development and testing of novel therapeutic approaches, with 
unexpectedly good results, previously thought to be impossible to achieve. The chapter will 
close with some considerations on the relevance and future perspectives of genetic testing in 
patients with intellectual disability. 
2. Intellectual disability – definition and classification 
Intellectual disability is one of the most frequent and disabling neurological impairments 
in school-age children, with an estimated prevalence of 1.5-2% in Western countries 
(Leonard and Wen, 2002). In developing countries it tends to be even more frequent, due 
to environmental factors such as poor health care and malnutrition, among others 
(Durkin, 2002). The diagnosis of intellectual disability is built upon three main criteria: I) 
significant sub-average general intellectual functioning; II) limitations in adaptive 
behaviour in at last 2 of the following skills: communication, self-care, home living, 
social/interpersonal skills, use of community resources, self-direction, functional 
academic skills, work, leisure, health and safety; III) onset of the symptoms before 18 
years of age (Salvador-Carulla et al., 2008). According to the International Classification of 
Disease, intellectual disability is defined as a “condition of arrested or incomplete 
development of the mind, which is specially characterized by impairment of skills 
manifested during the developmental period, skills which contribute to the overall level 
of intelligence, i.e. cognition, language, motor and social abilities” (World Health 
Organization, 2007). The classification of intellectual disability is mostly based on the 
measurements of Intellectual Quotient (IQ) tests.  In the general population IQ is normally 
distributed with a mean at approximately 100. It is accepted that when an individual 
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presents an IQ lower than 70, this person is classified as intellectually handicapped. The 
severity of intellectual disability can be divided into mild (IQ between 50 and 69), 
moderate (IQ of 35-49), severe (IQ of 20-34) and profound intellectual disability (IQ lower 
than 20) (Salvador-Carulla et al., 2008). Severe to profound intellectual disability has an 
estimated prevalence of 0.3-0.5% (Leonard and Wen, 2002). 
Conventionally, and from a clinical perspective, intellectual disability may be subdivided 
into two major categories – syndromic, characterized by associated clinical, radiological, 
metabolic or biological features, and non-syndromic forms of intellectual disability in which 
the cognitive impairment represents the only manifestation of the disease. This distinction is 
very useful from the clinical perspective, although some studies have shown that the 
boundaries between syndromic and non-syndromic forms are not strict. Several genes have 
been identified that are associated with both types of phenotypic presentation (Frints et al., 
2002). Although this may be an artificial classification, for discussion purposes some 
researchers have also defined three major groups of intellectual disability associated 
disorders: metabolic syndromes, syndromes with intellectual disability and associated 
malformations/dysmorphisms and syndromes with intellectual disability and 
neurological/neuromuscular symptoms (Chiurazzi et al., 2008). 
3. Metabolic causes of intellectual disability 
Metabolic disorders or inborn errors of metabolism (IEM) designate a wide group of 
diseases caused by genetic defects leading to alterations of metabolism. These are estimated 
to be responsible for 1– 5% of non-syndromic intellectual disability (García-Cazorla et al., 
2009). The majority arise from mutations in single genes that code for enzymes, resulting in 
abnormal or reduced enzyme activity. As a consequence, some undegraded substrates may 
accumulate and built up to toxic levels. It can also occur that some compounds that are 
required for normal cellular metabolism cannot be produced. As with many genetic 
conditions, inborn errors of metabolism are individually rare but as a group can reach an 
incidence of 1:4000 (Applegarth et al., 2000).  
Although intellectual disability is a common theme in metabolic disorders, very few 
present intellectual disability as the only clinical feature. Other neurological findings such 
as regression, ataxia, seizures, movement disorders or behavioural problems are usually 
present, as well as other organ related symptoms. Taking into consideration what is 
currently known about intellectual disability related genes, it is accepted that intellectual 
disability can stem from two broad mechanistic themes: dysfunction of 
neurodevelopmental programs and alterations in synaptic organization and plasticity 
(Vaillend et al., 2008; Kramer and van Bokhoven, 2009). Metabolic alterations present in 
metabolic disorders can theoretically affect both mechanisms, depending on the age at 
which the toxicity/deficiency begins to manifest (prenatal, early or late infancy, 
adolescence), and the specific defect itself (energy deficiency, storage disorders). For 
instance, diseases of energy availability, such as creatine and glucose transport deficits, 
are associated with mild/moderate intellectual disability. On the other hand, altered 
production of neurotransmitters in glycine, serine and biogenic amine disorders, is 
usually associated with severe mental and motor deficits (García-Cazorla et al., 2009). In 
inborn errors of metabolism leading to storage of toxic compounds, such as urea cycle 
disorders, organic acidurias, or lysosomal storage disorders, the level and duration of 
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exposure to toxic agents can dictate different degrees of mental disability. The most 
common inborn error of metabolism associated with intellectual disability is 
Phenylketonuria (PKU), with an average worldwide estimated prevalence of 1:10000 
(Hardelid et al., 2008). Phenylketonuria results from deficient activity of the enzyme 
phenylalanine hydroxylase, which converts phenylalanine to tyrosine (Kahler and Fahey, 
2003). Other less common disorders include deficiency of the creatine transporter SLC6A8 
(Salomons et al., 2001) and mutations involving the thyroid hormone transporter MCT8 
(Dumitrescu et al., 2004) and the ATP7A gene, which is implicated in occipital horn 
syndrome, a mild variant of Menkes syndrome (OMIM 309400) (Tümer et al., 1999). 
4. Chromosomal rearrangements in intellectual disability: From classic 
syndromes to the discovery of new microdeletions and microduplications  
Chromosomal aberrations can be numeric or structural. Numeric aberration can stem from 
the loss/gain of an entire chromosome (leading to the monosomy or trisomy) or of the 
whole chromosome complement (given rise to triploidy and tetraploidy). In general, the 
absence of a chromosome is far more drastic than its excess. These consequences are not the 
same for autosomal and sexual chromosomes since the absence of an entire autosomal 
chromosome is not compatible with life whereas the same alteration in a sexual 
chromosome may result in a live born female (e.g. 45,X – Turner syndrome). Structural 
variation is a term used to describe all types of genomic rearrangements, including 
deletions, duplications, insertions, inversions, translocations, loss of heterozygosity and 
more complex alterations. Structural abnormalities are a consequence of double-strand 
breaks and inappropriate DNA repair. The most common form of structural variation in the 
genome are copy number variations – CNVs. 
4.1 Classic syndromes 
Classic syndromes are usually associated with chromosomal abnormalities and large 
structural variations, since this type of alterations is far more likely to lead to additional 
phenotypic presentations other than intellectual disability alone. Moreover, from a 
historical perspective, classical cytogenetic methodologies (karyotyping, fluorescent in 
situ hybridization) are poorly suited for the detection of very small alterations. The most 
common single cause of intellectual disability is Down syndrome (trisomy 21; OMIM 
190685), with an estimated prevalence of 1:750-1:800 and described for the first time in 
1866, by J. Langdon Down (Down, 1995). In addition to mental impairment, Down 
syndrome patients may present other phenotypic characteristics such as the easily 
recognizable facial appearance, congenital malformations, hearing loss and early onset 
Alzheimer's disease (Epstein, 2001). The identification by Jérôme Lejeune of trisomy of 
chromosome 21 as the cause of this syndrome opened the way to genetics studies and 
genotype-phenotype correlations in patients with intellectual disability. Although other 
alterations are far less common than trisomy 21, cytogenetically visible chromosomal 
alterations are estimated to account for up to 15% of intellectual disability cases (Leonard 
and Wen, 2002). Other well-known syndromes with recognizable clinical features include: 
Prader-Willi, Angelman, Smith-Magenis, Miller-Dieker and DiGeorge (Ropers, 2010). 
Table 1 summarizes some examples of syndromes and chromosomal alterations 
associated with intellectual disability. 
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Syndrome Chromosomal  abnormality OMIM Clinical hallmarks 
Down trisomy 21 190685 
Intellectual disability and characteristic 
facies, congenital malformations of the heart 
(30-40%), significant hearing loss (90%),  
early onset Alzheimer disease 
Prader-Willi del15q11-q13 176270 
Diminished fetal activity, obesity, muscular 
hypotonia, intellectual disability, short 
stature, hypogonadotropic hypogonadism, 
and small hands and feet 
Angelman del15q11-q13 105830 
Intellectual disability, movement or balance 
disorder, characteristic abnormal 
behaviours, and severe limitations in speech 
and language 
Smith-Magenis del17p11.2 182290 
Brachycephaly, midface hypoplasia, 
prognathism, hoarse voice, speech delay 
with or without hearing loss, psychomotor 
and growth retardation, and behavioral 
problems 
Miller-Dieker del17p13.3 247200 
Classic lissencephaly,  microcephaly, cardiac 
malformations, hypoplastic male extrenal 
genitalia, growth retardation, and 
intellectual disability with seizures 
DiGeorge del22q11.2 18840 
Neonatal hypocalcemia, susceptibility to 
infection, cardiac malformations, 
micrognathia may be present, low set ears, 
short philtrumm, small mouth, short stature, 
variable mild to moderate learning 
difficulties 
Edwards trisomy 18 - 
Kidney malformations, structural heart 
defects at birth, intestines protruding 
outside the body, esophageal atresia, 
intellectual disability, developmental delay, 
growth deficiency, microcephaly,  
micrognathia, cleft lip/cleft palate, upturned 
nose, narrow eyelid folds, drooping of the 
upper eyelids clenched hands 
Williams-
Beuren del7q11.23 194050 
Supravalvular aortic stenosis, intellectual 
disability, and distinctive facial features: 
„elfin face“ 
Table 1. Examples of syndromes and chromosomal alterations associated with intellectual 
disability. 
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4.2 New microdeletion and microduplication syndromes 
For many years, genomic DNA copy-number variants (CNVs) such as deletions and 
duplications were assumed to be few and to have limited impact on the total content of 
human genetic variation. With the development and improvement of genome-wide 
analysis tools to study the genome, such as array comparative genomic hybridization (see 
below), it has been shown that copy-number variants are relatively frequent, spread 
throughout the genome and represent a very significant source of genetic variation in 
human populations. As of now, thousands of heritable copy number variations have been 
identified, in regions of potential variability corresponding to 14.3% of the human genome 
(Li et al., 2009). These are often sporadic and caused by de novo rearrangements. It is 
accepted that these types of variations can occur at a 1000 to 10.000 higher frequency than 
point mutations (Kumar, 2008). Although copy-number variants occur at similar 
frequencies between populations, several significant differences in the frequency of some 
CNVs were found between different populations in the world, suggesting that variations 
in the genomic architecture account not only for disease, but also for ethnic differences 
and selective evolution (Li et al., 2009). The developments in array comparative genomic 
hybridization technologies allowed genome-wide studies in patients with intellectual 
disability, and as a consequence, the rate of discovery of new microdeletion and 
microduplication syndromes has substantially increased. For instance, several studies 
were able to identify new pathogenic copy-number variants in up to 15% of patients with 
non-syndromic intellectual disability and normal karyotype (Friedman et al., 2006; Koolen 
et al., 2009; Jaillard et al., 2010). A current search on the DECIPHER database of 
submicroscopic chromosomal imbalance (http://decipher.sanger.ac.uk/) yields 46 
entries/syndromes with intellectual disability. Some of these copy-number variants are 
surprisingly common, such as the microdeletion in the 1p36.1 region, found in 1% of non-
syndromic patients (Battaglia et al., 2008).  
4.3 Array comparative genomic hybridization technology 
Microarray technology was developed more than a decade ago and has now become a 
routine tool in genetic research. This methodology was first used in the Clinical Genetics 
field for the analysis of copy-number variants in all human telomeres in patients with 
intellectual disability. Since then, array comparative genomic hybridization (aCGH) has 
been adopted by hundreds of genetic laboratories, using platforms that now target the entire 
genome (Heller, 2002). 
In an aCGH experiment, DNA from a test sample (e.g. patient with intellectual disability) 
and a reference DNA (healthy individual) are labelled with different fluorescent dyes and 
hybridized with DNA probes that can represent either regions or the entire genome. These 
arrays are generally performed on glass slides, silicon or plastic substrates and can contain 
hundreds to many thousands of probes. The construction of the array slides involves the 
physical immobilization of previously selected and synthetically generated probes onto 
specific sites of the solid support (Ylstra et al., 2006). As reference and test samples are 
labelled with different fluorophores, hybridization with genomic probes will result in 
distinct fluorophore intensity for test and reference DNA. It is this fluorescence ratio that 
translates the amount/type of copy number variation present in the sample.  
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The majority of aCGH data available today in public databases and published articles 
originated from studies using Bacterial Artificial Clone-based CGH (BAC arrays). BAC 
probes vary from 150 to 200 Kb and require high amounts of DNA for hybridization, having 
been superseded by oligonucleotide-based arrays (oligo arrays), which are considered to 
have large advantages over the BAC arrays. These platforms are characterized by single-
stranded oligonucleotides (25 to 85 bp in length) attached to the array slide, allowing the 
detection and analysis of copy-number variation with a much higher resolution (Neill et al., 
2010). The development of the aCGH platforms has led to an important increase in the 
detection of copy number variations. The spatial resolution of the array is determined by the 
sensitivity, the number, the chromosomal distribution and the length of the probes in the 
array. As such, platforms with shorter probes will allow more probes in the same space, 
leading to higher resolution. With the increasing awareness of the impact of copy number 
variations in disease and the growing number of international databases and population 
studies regarding pathogenic and non-pathogenic variations, these higher resolution 
platforms are now widespread and used in routine procedures. aCGH is currently the 
recommended approach for diagnosis of intellectual disability by international guidelines 
and is already used as a first-tier test in the USA and several European countries (Li and 
Andersson, 2009). The successful implementation and use of aCGH technologies requires 
the use of techniques for synthesis and spotting of the probes in the most effective locations, 
detection of hybridized samples and many statistical methods and informatic analysis of the 
resulting data. The informatic analysis usually requires the detection of the ratio of the 
signal generated at each probe location in the test and control sample. Several bioinformatic 
tools have been developed and are now available to transform the complex aCGH data and 
artefacts into useful information (van de Wiel et al., 2009; van Wieringen et al., 2007; Gai et 
al., 2010). 
5. Monogenic forms of intellectual disability: X-linked and autosomal 
5.1 X-linked intellectual disability 
X-linked intellectual disability (XLID), although a heterogeneous group, is perhaps the most 
widely studied form of intellectual disability. This is mostly due to the fact that the X-linked 
mode of inheritance is easy to identify and also because, although the human X-
chromosome only harbours about 4% of the protein coding genes of the human genome, X-
chromosomal defects are estimated to account for approximately 10% of the intellectual 
disability seen in males (Ropers and Hamel, 2005). In fact, the use of target sets of XLID or 
simply X-chromosome genes to screen for new X-linked intellectual disability mutations or 
genes in undiagnosed patients has proved to be an effective approach (de Brouwer et al., 
2007; Tarpey et al., 2007). To date more than 90 genes have been associated with XLID, either 
syndromic, non-syndromic forms of intellectual disability or both. For instance, mutations in 
the ARX gene, the second most common cause of X-linked intellectual disability (after 
FMR1/Fragile X) can be associated with both syndromic and non-syndromic intellectual 
disability (Gécz et al., 2006).  
The most common form of X-linked intellectual disability, and also “overall” monogenic 
intellectual disability, is the Fragile-X syndrome which is estimated to affect up to 
approximately 1:2500 individuals (Hagerman, 2008). This syndrome is characterized by 
intellectual disability, development delay, hyperactivity, hypersensitivity to stimuli, mood 
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instability and autism. The Fragile-X syndrome is caused by the expansion of the 
trinucleotide repeat CGC at FMR1 gene in the X chromosome, leading to the absence of 
FMRP protein. FMRP is an RNA binding protein that shuttles between the nucleus and the 
cytoplasm. It is thought that FMRP plays an important role in synaptic plasticity through 
regulation of mRNA transport and translational inhibition of local protein synthesis at 
synapses (Fatemi and Folsom, 2011). Studies in patients and animal models of Fragile-X 
syndrome have identified increased spine density and an excess of abnormal long, thin and 
immature spines which are indicative of alterations in synapse development and/or 
function in these patients (Krueger and Bear, 2011). 
5.2 Autosomal intellectual disability 
As intellectual disability affected individuals commonly possess low reproductive fitness, 
severe autosomal dominant intellectual disability is most often due to de novo mutations. 
Taking into account the high frequency of de novo pathogenic copy-number variations found 
in non-syndromic intellectual disability, autosomal dominant intellectual disability is 
unlikely to be rare. However, while several well-known autosomal dominant disorders such 
as neurofibromatosis, tuberous sclerosis and myotonic dystrophy are often associated with 
intellectual disability of varying severity (Nelson, 2009), very little is known about the gene 
defects underlying non-syndromic autosomal dominant intellectual disability. On the other 
hand, mounting epidemiological data suggests that autosomal recessive forms may also be 
very common, although frequencies for each individual gene should be rare (Ropers, 2007). 
More than 1400 autosomal intellectual disability genes are estimated to exist (Raymond, 
2010). For instance, a search for the terms “mental retardation” or “intellectual disability” on 
OMIM (Online Mendelian Inheritance of Man; http://www.ncbi.nlm.nih.gov/omim) yields 
815 entries for conditions with known molecular basis or gene on autosomal chromosomes, 
while an unrestricted search for the same terms yield 1308 entries for autosomal 
chromosomes. The classical approach for identifying autosomal recessive intellectual 
disability associated genes is homozygosity mapping in consanguineous families. This has 
made the search for new autosomal recessive intellectual disability genes very difficult as in 
Western societies, where most research takes place, families are usually small and most 
patients are isolated cases. In countries such as Iran, where consanguinity is more common, 
several studies revealed more than 30 loci for autosomal recessive intellectual disability, 
highlighting the heterogeneous character of this condition (Ropers, 2010). The massification 
of high resolution aCGH and the maturation of next generation sequencing technologies 
(see below), will certainly provide a new thrust to the identification of novel intellectual 
disability-associated genes.  
6. Recent technological advances: Massive Parallel Sequencing 
Technological advancements in the last decade have brought enormous progress, not only 
in the field of array-technology, but perhaps even in a more striking way in DNA 
sequencing. Sanger sequencing has for decades been the standard method for DNA 
sequencing. However, despite several improvements throughout the years, its basic process 
is not adequate for fast and complete sequencing of one or multiple genomes (Schuster, 
2008). Several new and improved technologies have emerged in recent years to cope with 
these new expectations – fast, low cost and high-throughput - so called Next Generation 
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Sequencing or Massive Parallel Sequencing (NGS/MPS). Massive Parallel Sequencing 
technologies have fundamental differences compared to conventional Sanger sequencing, 
relying on different technical approaches and usually requiring a previous enrichment step. 
MPS is based on sequencing clonally amplified single molecules of genomic DNA that need 
between 10-50 reads of the same base to reliable identify heterozygous sequence variants 
since every read shows only one of the possible two alleles in the sequence.  
Massive parallel sequencing has led to the development of new strategies in the analysis of 
monogenic diseases, allowing the identification of causative mutations in diseases in which 
they were previously impossible to identify through classical linkage analysis or positional 
cloning due to insufficient family information. Moreover, it can also be applied to the 
detection of copy-number variants and provide an effective replacement for aCGH 
(Medvedev et al., 2009). When speaking of MPS, one must take into consideration that it can 
be applied not only to the sequencing of a complete genome, but also to a subset of genomic 
regions of a set of target genes, which due to factors such as cost/speed can be much more 
effective approaches than full genomic sequencing. Exome sequencing for instance, 
comprehends the capture, sequencing and analysis of only the protein-coding regions of the 
genome (1% of the whole genome) and has seen increasing adoption by researchers for the 
identification of new disease genes. The use of exome capture to focus on a critical part of 
the human genome, allows the study of larger numbers of samples than those currently 
practical to analyse with whole-genome sequencing (Teer and Mullikin, 2010).  
Since current classical approaches seem incapable of identifying/explaining a huge amount 
(60%) of the genetic aetiology of intellectual disability (Rauch et al., 2006), these technologies 
are already having a great impact in the field. In recent years, exome sequencing has 
allowed researchers to identify several new genes involved in intellectual disability, 
encompassing diverse models of inheritance and phenotype (Hoischen et al., 2010; Ng et al., 
2010; Vissers et al., 2010). Unlike standard strategies, by avoiding the use of a predefined set 
of target genes or genomic regions, the likelihood of finding new genes acting in unexpected 
biological pathways is greatly increased. Moreover, these studies are often successful in the 
analysis of very few or even single disease patients, which is of relevance since many cases 
of intellectual disability occur as isolated cases in families without previous clinical history. 
Although the advantages of massive parallel sequencing seem very clear, there are many 
challenges brought up by these technologies that need to be overcome. Due to the fact that 
MPS approaches generate vast amounts of data, the biggest challenge is, of course, 
interpretation. Researchers need to be able to accurately distinguish the disease-associated 
variations from the benign and evolution-related aspects of the genome. This will be 
facilitated by the adoption of standardized analytical procedures and the development of 
catalogues or databases of genetic variance in both diseased and healthy individuals from 
different ethnic backgrounds. In the following years, as the affordability and practical 
implementations of these technologies improves, massive parallel sequencing will 
theoretically allow us to identify mutations in patients with intellectual disability, regardless 
of inheritance and frequency of phenotype. 
7. Cellular pathways involved in intellectual disability 
The increasing number of genes identified over the last years associated with intellectual 
disability suggests that this phenotype can emerge as the final common pathway of many 
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different types of abnormal cellular processes, putting to rest the hypothesis of a single main 
general mechanism responsible for the disease. This is in a way consistent with the 
complexity of intellectual processing in humans. To date, taking into consideration what is 
currently known about intellectual disability related genes, in particular monogenic forms of 
intellectual disability, it is considered that this disease can stem from two broad mechanistic 
themes: dysfunction of neurodevelopmental programs and alterations in synaptic 
organization and plasticity (Vaillend et al., 2008; Kramer and van Bokhoven, 2009).  
7.1 Neurogenesis 
During development, neurogenesis and cell migration occurs in a tightly controlled spatio 
temporal manner, during which neurons form intricate axonal and dendritic connections. 
The accuracy of this process results from both intrinsic genetic characteristics and functional 
cell-to-cell interactions. Small disruptions in any of these processes during development can 
lead to cognitive dysfunction in children.  
During embryonic development, the first formed neurons arise from two different 
daughter cells: one that gives rise to a neuron that will migrate to the cortex, and another 
cell that continues to proliferate as a stem cell. It is now known that although in the 
cerebral hemispheres the majority of neurogenesis occurs in the first half of gestation, 
neurogenesis also occurs in the olfactory bulb, sub-ventricular zone and hippocampus in 
adults (Diaz and Gleeson, 2009). Defects in the control of neuronal number, from excess or 
defects in germinal epithelial proliferation can lead to disorders such as macro- or 
microcephaly. These diseases comprise a heterogeneous group of disorders that can be de 
novo or familial, often associated with increased incidence of cognitive impairments 
(Adachi et al., 2011). 
Microcephaly is characterized by a reduced frontal-occipital head circumference, more than 
3 standard deviations below the mean of age and sex-matched controls. It can be classified 
as primary or secondary (acquired or traumatic). Patients with primary microcephaly 
usually display small but architecturally normal brains or with mildly simplified gyral 
patterns, and have mild intellectual disability (Clowry et al., 2010). Microcephaly is known 
to be associated with mutations in at least 4 genes (MCPH1, ASPM, CDK5RAP2 and CENPJ), 
all associated with cell division and cell cycle regulation. But whereas microcephalin 
(MCPH1) is a DNA damage response protein that plays a role into preventing premature 
entry into mitosis (Alderton et al., 2006), ASPM, CDK5RAP2 and CENPJ are located to the 
spindle poles of mitotic cells and are involved in mitotic spindle dynamics and cellular 
abscission (Bond et al., 2005; Fish et al., 2006; Paramasivam et al., 2007). The role of adult 
neurogenesis in cognition is still a matter of debate, but it is possible that milder disruption 
of genes involved in neurogenesis, even if it does not disrupt development of the nervous 
system, may impair cognition through yet unknown mechanisms (Bruel-Jungerman et al., 
2007). 
7.2 Neuronal migration 
Diseases of neuronal migration comprise a heterogeneous group of disorders of the nervous 
system development and represent a significant cause of intellectual and developmental 
disability and epileptic seizures in childhood (Verrotti et al., 2010). After neurogenesis, post- 
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mitotic neurons are organized in columns and migrate away from the ventricular zone in a 
radial pattern to their final destination in the forming cerebral cortex (Diaz and Gleeson, 
2009). Strict regulation of the timing and pattern of neuronal migration is essential for a 
correct development and intellectual functioning. Abnormal migration dynamics leading to 
incorrect distribution of neurons in the cerebral cortex is the cause of several disorders 
characterized by cortical dysgenesis, such as lissencephaly.  
Lissencephaly (which literally means “smooth brain”) refers to the occurrence of a smoother 
brain surface without gyri or sulci and it is associated with severe intellectual disability and 
refractory epilepsy (Verrotti et al., 2010). Classical type 1 lissencephaly can be caused by 
mutations in LIS1 and DCX genes, among others. LIS1 is an autosomal gene that encodes the 
LIS1 protein, a microtubule associated protein. LIS1 is known to interact with cytoplasmic 
dynein, phosphoprotein NDEL1 and kinetochore CLIP-170, as part of a complex important 
for neuronal migration (Wynshaw-Boris, 2007). DCX on the other hand is an X-linked gene 
exclusively expressed in post-mitotic neurons. DCX encodes the doublecortin protein, 
proposed to be involved in vesicle trafficking and the growth of neuronal processes 
(Friocourt et al., 2003). TUBA1 (α1 tubulin) is also a lissencephaly-associated gene, which 
reinforces the role of microtubule associated proteins in the processes of neuronal migration 
(Keays et al., 2007).  
 
Type of Lissencephaly Associated syndrome Underlying genes 
Type I Lissencephaly ⋅ Isolated lissencephaly sequence 
⋅ Miller-Dieker syndrome 
⋅ LIS1, DCX, TUBA1A,  
⋅ LIS1 and YHAWAE 
  deletion 
Cobblestone Lissencephaly ⋅ Walker-Warburg syndrome 
⋅ Muscle-Eye-Brain disease 
⋅ Fukuyama congenital muscular
  dystrophy 
⋅ POMT1, POMT2, FKTN,  
⋅ FKRP 
⋅ LARGE, FKTN 
 
X-linked lissencephaly with 
agenis of corpus callosum 
(XLAG) 
⋅ Lissencephaly ⋅ ARX 
Lissencephaly with 
cerebellar hypoplasia (LHC)
⋅ Lissencephaly ⋅ RELN, VLDLR 
Microlissencephaly ⋅ Norman-Roberts syndrome 
⋅ Barth syndrome 
⋅ Primordial osteodysplastic 
  dwarfism and microcephaly 
  (MOPD type 1) 
Not described 
Table 2. Classification of lissencephalies, syndromes and associated genes. Adapted from 
(Verrotti et al., 2010b). 
Another well studied intellectual disability gene is RELN, associated with lissencephaly with 
cerebellar hypoplasia and rare forms of pachygyria. Reelin, however, is not related to 
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microtubules: it is an extracellular matrix protein of migrating neurons. Reelin, along with 
Dab1, participates in a signalling pathway critical for the end stage of neuronal migration 
(Kerjan and Gleeson, 2007). 
Other diseases associated with the Reeling pathway are the cerebellar ataxia, intellectual 
disability, and dysequilibrium syndrome (CAMRQ1, OMIM 221050), and the Uner Tan 
syndrome, characterized by a similar phenotype and possessing quadrupedal locomotion 
(Uner Tan, 2010). CAMRQ1 and Uner Tan syndrome are caused by mutations in the VLDLR 
gene which encodes the very low density lipoprotein receptor (Ozcelik et al., 2008). In mice, 
Vldlr has been shown to be a direct binding partner of Reelin and lack of Vldlr impairs 
Reelin-induced Dab1 phosphorylation (Trommsdorff et al., 1999). 
7.3 Synaptic function 
Chemical synapses regulate the electrical communication within neurons and allow the 
flow of information from presynaptic axon terminals to postsynaptic dendritic regions. 
Most excitatory synapses in the brain are formed at tiny dendritic protrusions called 
dendritic spines (Hotulainen and Hoogenraad, 2010). The molecular architecture of 
chemical synapses consists of presynaptic axon terminals harbouring synaptic vesicles 
and a postsynaptic region (on dendrites) containing neurotransmitter receptors. The 
presynaptic and postsynaptic sites are separated by the synaptic cleft (10 to 25 nm) and a 
variety of cell adhesion molecules (CAMs) hold them together at the proper distance 
(Price et al., 2006). These cell adhesion molecules, such as neurexins and neuroligins, are 
involved in the formation of functional presynaptic regions specialized in vesicle fusion to 
the plasma membrane and correct release of the neurotransmitters to the synaptic cleft. 
While neurexins are presynaptic receptors, neuroligins are the ligands of neurexins 
located in the postsynaptic side. Mutations in NLGN3/4 (neuroligin 3/4) gene were found 
in patients with intellectual disability and/or autism spectrum disorders (ASDs) (Vaillend 
et al., 2008). NLGN4 is involved in formation of active regions at presynaptic terminals 
through interactions with its presynaptic receptor β-neurexin. It is worth noting that other 
proteins belonging to the neurexin superfamily, such as CNTNAP2 or interaction proteins 
such as APBA2 have been implicated in autism spectrum disorders and schizophrenia, 
suggesting that synaptic dysfunction may be a common theme among these disorders 
(Ropers, 2008). Interestingly, some molecules known to be involved in axonal pathfinding 
are now known to play a role also in synapse stabilization, one example being ephrins 
(Shen and Cowan, 2010). 
On the presynaptic region, neurotransmitters such as glutamate or γ-aminobutyric acid 
(GABA), are produced and stored in synaptic vesicles. The docking and fusion of the 
vesicles to the membrane is controlled by the  SNARE (soluble N–ethylmalei–mide–
sensitive factor attachment protein receptor) complex. Many other presynaptic proteins 
play a role not only in the synaptic vesicle fusion process but also in other steps of 
synaptic vesicle trafficking such as targeting, docking and priming (Lin and Scheller, 
2000). Information about the mechanisms of synaptic vesicle docking and fusion are a key 
to understand synaptic transmission itself and also to discover the transmission 
modifications that may play a role in synaptic plasticity, learning and memory (Chechlacz 
and Gleeson, 2003). 
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Gene Protein Locus Function
NRXN1 NRXN1 2p16.3 Cell adhesion molecule 
NLGN4 NLGN4 Xp22.33 Cell adhesion molecule 
STXBP1 Syntaxin-binding 
protein 1 
9q34.1 Synaptic vesicle docking and 
fusion, release of 
neurotransmitters 
GDI GDIα Xq28 Regulator of Rab GDP-GTP state, 
vesicle trafficking, release of 
neurotransmitters 
RAB3GAP1 Rab3-GAP 2q21.3 Regulator of Rab GDP-GTP state, 
vesicle trafficking, release of 
neurotransmitters
GLIA3 Glutamate receptor 3 Xq25 Ionotropic glutamate 
neurotransmitter receptor 
SAP102/DLG3 Synapse-associated 
protein 102/ Discs 
large homolog 3   




11q13.2 Molecular scaffolds in the 







Regulation of calcium-dependent 
exocytosis, secretion and 
presynaptic differentiation 
DMD Dystrophin  Xp21.2 Synapse stabilization,  anchoring 
of postsynaptic receptors and 
transducing signals
PAK3 Serine/threonine-
protein kinase PAK 3  
Xq23 Regulator of synapse formation 
and plasticity
PRSS12 Protease, serine, 12 4q28.1 Serine protease, neuronal 
plasticity 
GRIK2 Glutamate receptor, 
ionotropic, kainate 2 
6q16.3-q21 Ionotropic glutamate 
neurotransmitter receptor 
Table 3. Examples of ID-associated genes coding for synaptic proteins. 
STXBP1 (syntaxin-binding protein 1) encodes a neuronal specific syntaxin-binding protein 
and has been found to be mutated in patients with autosomal dominant intellectual 
disability and epilepsy (Hamdan et al., 2009). STXBP1 is also a regulatory protein of 
VAMP2, syntaxin 1 and SNAP,  key elements of the synaptic vesicle docking and fusion 
machinery (Lin and Scheller, 2000).The key regulator of vesicle trafficking is Rab GTPase 
activity, which is under the control of specific GAPs (GTPases-activating proteins), GEFs 
(guanine-nucleotide-exchange factors) and GDIs (guanine-nucleotide-dissotiation-
inhibitors). These molecules mediate vesicle trafficking and fusion by modulating the 
association/dissotiation of Rab proteins to vesicles through control of their GDP-bound 
state (Renieri et al., 2005). Several intellectual disability related proteins are known to 
intervene in this process. Of notice, the GDI gene, associated with X-linked intellectual 
disability, encodes the GDIα protein which regulates the sequestration of GDP-bound Rab 
proteins. Moreover, studies in mice models have shown that lack of GDIα leads to altered 
 
Molecular Genetics of Intellectual Disability 
 
161 
Rab4/5 distribution and impaired short-term memory (D’Adamo et al., 2002). Rab3 for 
instance, has been shown to be regulated by Rab3 GAP, a protein involved in Warburg 
Micro syndrome, characterized by abnormal brain development and severe intellectual 
disability (Aligianis et al., 2005). In animal models, mutated Rab3 GAP has been shown to 
lead to accumulation of GTP-bound Rab3 and result in inhibition of glutamate release and 
altered short-term plasticity (Sakane et al., 2006). 
The dendrites are home to the post-synaptic machinery/density, which includes 
neurotransmitter receptors (e.g. glutamate receptors), cytoskeleton components, adapter 
proteins, endocytic machinery, chaperones as well as members of numerous regulatory 
pathways involved in differentiation of the post-synaptic regions and establishment of 
functional synapses (Vaillend et al., 2008). Approximately 20 X-linked intellectual disability 
associated genes code for postsynaptic proteins (Laumonnier et al., 2007). Some of these 
genes code for components or regulators of glutamate receptors, such as GluR3, SAP102 and 
PLP1. GluR3 for instance is a subunit of post-synaptic AMPA receptors, which plays a role 
in fast excitatory transmission, and has been involved in neurodegenerative disorders such 
as Parkinson's and Huntington's disease (Jayakar and Dikshit, 2004). As for SAP102, it is a 
member of membrane associated guanylate kinase (MAGUK) family of proteins and is 
required for recruitment of NMDA receptors. MAGUKs play a role in the regulation of the 
number of glutamate receptors at the synapse as well as the synaptic trafficking of these 
receptors during the morphological changes that are associated with synapse plasticity 
(Elias and Nicoll, 2007). Other components of the post-synaptic machinery are the Shank 
proteins - multidomain scaffold proteins connecting neurotransmitter receptors and other 
membrane proteins with signaling proteins and the actin cytoskeleton (Boeckers et al., 2002). 
They participate in morphological changes, leading to maturation of dendritic spines and 
synapse formation. Mutations in the SHANK2 (SH3 and multiple ankyrin repeat domains 2) 
gene have recently been described to be associated with intellectual disability and autism 
spectrum disorders (Berkel et al., 2010). 
7.4 Transcription regulation 
Gene expression and consequent protein synthesis is a tightly regulated process determined 
by the interplay of chromatin dynamics, transcriptional activators/repressors and the 
regulation of RNA splicing, export and degradation. Alterations in these mechanisms may 
result in the deregulation of gene expression. If this abnormal expression of genes occurs at 
critical developmental stages, it is likely that it will lead to defective brain development 
and/or functioning. Neurons are highly specialized cells in which some specific aspects of 
RNA metabolism play critical roles for their function specially, during development, when 
trafficking of mRNAs to growth cones (axonal and dendritic) regulates neuronal growth 
(Hengst and Jaffrey, 2007). After synapse formation, mRNAs continue to be transported to 
dendrites and axons where they are locally translated at the synapse (Martin and Zukin, 
2006). This process has extreme importance for synaptic plasticity, thought to be the 
biological correlate of memory/learning, and its deregulation can have an important impact 
on cognition.  
In fact, there are many examples of intellectual disability-associated genes that code for 
regulators of signal transduction pathways, transcription factors and cofactors involved in 
chromatin remodelling, gene expression and protein maturation (Santos et al., 2006; 
McClung and Nestler, 2007; Renieri et al., 2005).  
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g ATRX Xq13 ATPase/helicase Alpha-thalas semia syndrome 
CHD7 8q12.1 ATP-dependent 
chromatin remodeler 
CHARGE syndrome 










n CDKL5 Xp22 Dnmt1 phosphorylase West syndrome; Rett-like 
variant 
DNMT3B 20q11.2 NA methyltransferase Immunodeficiency, 
centromeric instability and 
facial dysmorphisms 
syndrome 















CREBBP 16p13.3 Histone acetyltransferase Rubinstein-Taybi syndrome 
EHMT1 9q34.3 Histone methyltransferase Kleefstra syndrome 
HUWE1 Xp11.2 Histone ubiquitin ligase Non-syndromic XLID 
MED12 Xq13 Histone methyltransferase 




PHF8 Xp11.2 Histone demethylase Siderius XLID syndrome 



















BRWD3 Xq13 Chromatin binding 
protein (putative) 
Non-syndromic XLID with 
macrocephaly 




ZNF41 Xp22.1 DNA-binding protein Non-syndromic XLID 
ZNF81 Xp221-p11 DNA-binding protein Non-syndromic XLID 
ZNF674 Xp11 DNA-binding protein Non-syndromic XLID 
ZNF711 Xq21.1 DNA-binding protein Non-syndromic XLID 
Table 4. Examples of transcription regulators genes known to be associated with intellectual 
disability. XLID, X-linked intellectual disability. 
For instance, the NF1 protein - associated with intellectual disability in neurofibromatosis 
type I (OMIM 162200), and the RSK2 protein - associated with Coffin-Lowry syndrome 
(OMIM 303600), act upon MAPK/ERK signalling. Whereas NF1 regulates MAP/ERK by 
targeting Ras, RSK2 (ribosomal protein S6 serine/threonine kinase) intervenes downstream 
in the Ras/ERK cascade and is involved in transcription activation through chromatin 
remodelling (Shalin et al., 2006). Other intellectual disability-associated genes can act in the 
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opposite direction. MeCP2 (methyl-CpG-binding protein 2, Rett syndrome), CDKL5 (cycling 
dependent kinase 5, Rett-like syndrome), ZNF41 (zinc finger protein 41, non-syndromic 
intellectual disability) and XNP (helicase 2, ATRX syndrome) proteins are involved in 
processes that repress transcription (Vaillend et al., 2008). MeCP2 and CDKL5 can both 
interact and mediate the silencing of specific genes through binding to methylated DNA, 
while ZNF41 contains a transcriptional repressor domain. Mutations in some RNA binding 
proteins are also known to account for some forms of intellectual disability. The most 
widely studied case is the FMRP protein, coded by FMR1, causative of Fragile X syndrome 
(Heulens and Kooy, 2011). FMRP is an RNA binding protein that associates with many 
mRNAs, some of which encode proteins important for neuronal development and plasticity. 
FMRP controls activity-dependent dendritic mRNA localization and translational efficiency 
of dendritic mRNAs in response to stimulation of metabotropic glutamate receptors 
(mGluRs) (Antar et al., 2004). 
Other molecules that are potential candidates for involvement in the pathology of 
intellectual disability are miRNAs, small non-coding RNA molecules (~21 bp) encoded in 
the genome that regulate gene expression by binding to the 3’UTR of specific target mRNAs 
(Corbin et al., 2009). Many of these miRNAs are expressed in the brain and seem to be 
essential for neuronal cell development, intervening in processes such as neurite outgrowth, 
synaptic development and neuronal plasticity. For example, miRNA miR132 has been 
shown to influence the Rac1-PAK-mediated spinogenesis and influence dendritic growth in 
hippocampal neurons (Hansen et al., 2010). Additionally, miR132 was also shown to 
regulate expression of MECP2, the gene responsible for Rett syndrome (OMIM 312750). 
Further data from miR132 overexpressing transgenic mice, confirmed decreased MeCP2 
protein expression and showed significant deficits in novel object recognition (Li et al., 
2008). It has been proposed that miR132 is a regulatory miRNA in neurons and may 
contribute not only for the cognitive defect in Rett syndrome, but also for a larger set of 
intellectual disability related disorders. As our current knowledge of the role that these 
processes play in synaptic plasticity and cognitive processes increases, so  we will better 
understand the importance of signalling components, transcription factors and chromatin 
regulation processes in intellectual disability. 
8. From human genetics to animal models and new therapeutic perspectives 
For some intellectual disability disorders the current state of knowledge on the underlying 
genetics and pathophysiology of the disease has already allowed the conception and 
development of some therapeutic approaches. These initial clinical results are very 
encouraging and the cases described below are good examples of how basic science, cell and 
animal model research can lead to the treatment of human diseases which were thought to 
be untreatable not many years ago. 
8.1 Rett syndrome 
Rett syndrome (RTT) is a neurodevelopmental disease associated with abnormalities in 
brain size, branching and synaptic morphology, neurotransmitter receptors and gene 
expression (Johnston et al., 2001). Clinically it is characterized by intellectual disability 
associated with other neurological features, breathing and cardiac function abnormalities, as 
well as growth impairment (Weaving et al., 2005).  Rett syndrome presents an X-linked 
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recessive mode of inheritance and an estimated incidence of 1:10000-1:15000 female births. It 
is mostly a sporadic condition, resulting from de novo mutations in the MECP2 gene. 
Duplications in MECP2 have also been reported in patients with diverse clinical 
presentation (Chahrour and Zoghbi, 2007). MeCP2 (methyl-CpG-binding protein 2) is a 
ubiquitously expressed transcription factor that binds methylated DNA. Although MeCP2 
was first characterized as a transcription repressor, it has been found that the majority of 
MeCP2-regulated genes are actually activated in the presence of this protein (Chahrour et 
al., 2008). With regard to links to cognition, MeCP2 has been shown to bind the 
transcriptional activator CREB1, known to be involved in learning and memory (Carlezon et 
al., 2005), and to repress the expression of BDNF, involved in synaptic transmission and 
plasticity (Chen et al., 2003). To allow a better understanding of the function of MeCP2 in 
brain development and consequently increase the knowledge of the pathophysiology of Rett 
syndrome, several disease mouse models have been generated. In general, these mouse 
models are able to recreate many physiological and neurological features of Rett syndrome 
(Calfa et al., 2011), and a number of therapeutic approaches have already been tested. Of 
notice, treatment of the Jaenisch mouse model with an active peptide fragment of Insulin-
like Growth Factor 1 (IGF-1) extendend the life span, improved locomotor function, 
ameliorated breathing patterns and reduced irregularities in heart rate of the animals 
(Tropea et al., 2009). IGF-1 activates pathways common to those induced by BDNF (Zheng 
and Quirion, 2004), and a clinical trial using IGF-1 in humans has already been initiated 
(NCT01253317). Direct modulation of BDNF levels with CX546, an ampakine drug, was also 
successful in restoring normal breathing parameters in Mecp2 null mice (Ogier et al., 2007). 
With regard to BDNF and neuronal function, application of exogenous BDNF was able to 
rescue Mecp2 mice-associated synaptic pathology, described has increased amplitude of 
spontaneous miniature and evoked excitatory postsynaptic currents in nucleus tractus 
solitarius neurons (Kline et al., 2010). In addition, treatment of Mecp2(stop/y) mice with the 
NMDA receptor blocker memantine was able to partially restore short-term synaptic 
plasticity (Weng et al., 2011). Another therapeutic approach being tested in humans involves 
treatment with desipramine (NCT00990691), a selective inhibitor of norepinephrin transport 
shown to improve breathing and survival in Mecp2-deficient mice (Roux et al., 2007) 
8.2 Fragile X 
Fragile X is the most common form of inherited intellectual disability with an estimated 
frequency of 1:2500-1:4000. It exhibits an X-linked recessive mode of inheritance and the 
clinical presentation includes mild to moderate intellectual disability, developmental delay, 
very defined dysmorphic characteristics, hyperactivity, hypersensitivity to stimuli, mood 
instability and autism (Hagerman, 2008). The Fragile X syndrome is caused by the 
expansion of the trinucleotide repeat (CGG) in the promoter of the FMR1 gene to >200 
repeats. This mutation results in the methylation and silencing of FMR1 and consequent 
absence of FMRP protein. FMRP is a multifunctional RNA binding protein thought to play 
an important role in synaptic formation and plasticity through the down regulation of the 
transport and translation of a wide subset of protein coding mRNA (>500 targets have been 
identified) at the dendrites (Berry-Kravis et al., 2011). This regulatory action is mainly 
dependent on activation by mGluR (group 1 metabotropic glutamate receptors) (Antar et al., 
2004). Several studies using animal models have shown that deregulated expression of 
FMRP targets at the dendrites results in enhanced mGluR-activated hyppocampal and 
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cerebellar long term depression (LTD), impaired long term potentiation (LTP) at the 
hyppocampus and cortex, and abnormal dendritic spine morphology (Berry-Kravis et al., 
2011). As such, group I mGluR signalling is thought to play a central role in the 
pathophysiology of Fragile X and is a major target for therapeutic intervention. Studies 
using Drosophila and mouse models of Fragile X have been very successful in 
demonstrating the efficacy of mGluR antagonists in the recovery of disease phenotypes even 
in adult animals (Yan et al., 2005; McBride et al., 2005). Another effective approach seems to 
be the modulation of the excitatory pathway through the GABAergic inhibitory pathways 
(Chang et al., 2008). While the impact of similar therapeutic strategies in human patients is 
still unknown, translation of these findings to the human context has begun and many 
clinical trials have been initiated that anticipate the possibility of effective treatments for X 
Fragile syndrome (http://clinicaltrials.gov/). 
8.3 Down syndrome 
Down syndrome (trisomy 21) is the most common single cause of intellectual disability, 
with an estimated prevalence of 1:750-1:800 (Hassold et al., 1996). In addition to mental 
impairment, Down syndrome patients may present other phenotypic characteristics such as 
the easily recognizable facial appearance, congenital malformations, hearing loss and early 
onset Alzheimer's disease (Epstein, 2001). Hypothetically, the additional copy of human 
chromosome 21 (Hsa21) should lead to an increased expression of many Hsa21 genes, 
resulting in the clinical phenotype associated with Down syndrome. However, not all of the 
more than 400 genes contained in the Hsa21 chromosome are bound to be dosage-sensitive 
(Gardiner and Costa, 2006). Identification of which specific genes are dosage-sensitive and 
responsible for the Down syndrome phenotype is being accomplished either through 
genomic association studies which try to draw genotype-phenotype correlations using 
patients with partial trisomy or other Hsa21 rearrangements (Lyle et al., 2009), and also 
through studies using animal models. Some prime candidates for trisomy 21 associated 
intellectual disability are DYRK1A, GIRK2, SYNJ1 and SIM2, which in several mouse models 
have been shown to be associated with learning and memory defects. Of notice, DYRK1A is 
a kinase which is involved in the phosphorylation of some synaptic proteins and many 
other kinases, known to play a role in intercellular signalling, endocytosis and cell cycle 
(Wiseman et al., 2009). In fact, gene therapy applied to the TgDyrk1A mouse model has 
shown that normalization of Dyrk1A gene expression was able to attenuate behavioural 
phenotypes, restore motor-coordination and improve sensorimotor gating (Ortiz-Abalia et 
al., 2008). Moreover, modulation of DYRK1A activity with the use of epigallocatechin gallate 
(EGCG), found in great amounts in green tea leaves, has proved successful in reverting 
DYRK1A-induced synaptic vesicle endocytosis defects in cultured hippocampal neurons 
(Kim et al., 2010) and rescuing the major phenotypic features of DYRK1A transgenic mice 
(Guedj et al., 2009). Following these positive outcomes, a human clinical trial has been 
recently completed, although no results have been published so far (NCT01394796). A more 
recent mouse model, TgRCAN1, also highlighted the impact of the overexpression of DSCR1 
(RCAN1), a functional inhibitor of calcineurin, in visuo-spatial learning and memory tasks 
similar to those present in Down syndrome affected persons (Dierssen et al., 2011). Other 
studies exploring the hypothesis of high levels of inhibition being involved in Down 
syndrome cognitive dysfunction also revealed promising results. Prolonged treatments with 
GABAA receptor antagonists, picrotoxin and pentylenetetrazole, resulted in a persistent 
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recovery of behaviour and cognitive deficits in adult Ts65Dn animals (Fernandez et al., 2007; 
Rueda et al., 2008). 
8.4 Tuberous sclerosis 
Tuberous sclerosis (TSC) is a multi-system disorder that causes benign tumours called 
hamartomas in the central nervous system and many other organs. Clinical manifestations 
include developmental delay, mental retardation, autism and epilepsy among other 
neurological problems. Tuberous sclerosis presents an autosomal dominant mode of 
inheritance and is estimated to affect 1:6000 individuals worldwide (Crino et al., 2006). As 
such, due to its severe clinical presentation, most cases arise from de novo mutations. The 
genetic basis for the disease has been linked to mutations in the TSC1 and TSC2 genes, 
coding for hamartin and tuberin respectively (Dabora et al., 2001). Initial studies in 
Drosophila provided the first links of the TSC1/TSC2 complex to the PI3K-Akt-mTOR-S6K 
pathway and further studies on mammalian systems eventually demonstrated that 
TSC1/TSC2 function as GTPase activating protein against Rheb – a Ras-like small GTPase, 
which in turn regulates TOR signaling in nutrient-stimulated cell growth (Pan et al., 2004). 
mTOR (mammalian target of rapamycin) is a serine/threonine protein kinase and a major 
regulator of cell growth and proliferation, cell motility, cell survival, protein synthesis, and 
transcription (Hay and Sonenberg, 2004). This suggested a possible therapeutic approach 
through the inhibition of mTOR. Several mouse models have been described that are able to 
reproduce, at least partially, the tuberous sclerosis phenotype (Ess, 2010). Recent 
publications using these animal models have provided promising data in support of the use 
of mTOR inhibition as a therapeutic strategy. The use of mTORC1 inhibitor rapamycin has 
successfully prevented epilepsy and premature death of Tsc1GFAP mice, homozygous for 
conditional knockout in astrocytes (Zeng et al., 2008). Similar effects were reported for the 
Tsc1Synapsin conditional knockout, which presents inactivation of Tsc1 in post-mitotic 
neurons, with near resolution of cell size defects and increased survival (Meikle et al., 2008). 
With regard to learning abnormalities, rapamycin was able to normalize impaired LTP and 
spatial learning in the Tsc2+/- heterozygous knockout mice (Ehninger et al., 2008). These 
positive results prompted researchers to suggest the use of rapamycin for treatment of 
tuberous sclerosis patients. As of now, several reports have been published that describe the 
regression of subependymal giant cell astrocytomas induced by mTOR inhibitors rapamycin 
and everolimus (RAD001) (Franz et al., 2006; Micozkadioglu et al., 2010; Birca et al., 2010; 
Krueger et al., 2010). No data has been published with regards to cognitive deficits so far. 
However, several clinical trials are undergoing that should provide a more complete 
evaluation of the efficacy of mTOR inhibitor treatment for tuberous sclerosis complex. 
9. Genetic diagnosis of intellectual disability in the clinical context: costs vs. 
benefits; New challenges 
A child with intellectual disability should be offered the best diagnostic evaluation available 
in order to improve the health and well-being of that child and his/her family. An adequate 
and precise diagnosis can be used by the family in obtaining information about a prognosis, 
recurrence risks and available therapy. In addition, it will provide an answer and 
appeasement to the common uncertainty and fear shared by many parents as to the origin of 
the disease (Barr and Millar, 2003). From a clinical perspective, establishing a diagnosis will 
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allow a better understanding of the prognosis and future needs, improvement of the 
response by medical and educational services by passing on the patients to an appropriated 
specialist and also to make future reproductive decisions based on appropriate estimated 
recurrence rate. At a scientific level, a specific diagnosis may provide potential insight into 
disease mechanisms and eventual development of therapeutic interventions. 
Currently, the extensive genetic heterogeneity of intellectual disability hampers the accurate 
diagnosis with classic technologies. New benefits and also challenges to the diagnosis field 
come from the advent of technologies such as high resolution aCGH and, most importantly, 
next generation sequencing. The application of these new technologies to clinical diagnosis 
is still limited, mostly due to the prohibitive costs they still imply when considering their 
application to full-scale diagnosis. This will likely change in the short term, as there is a 
huge effort from biotech companies to deliver the so called “$1000 genome” in the scope of 
1-2 years, and to scale the cost down even further as technology matures. This should allow 
a much higher rate of detection at a fraction of the price it now costs to cover all diagnostic 
hypothesis through classical techniques (e.g. regular karyotype analysis plus a customized 
FISH, such as subtelomeric FISH). The advent of aCGH and massive parallel sequencing is 
also changing current clinical diagnosis approaches. As these methodologies become more 
efficient in the identification of the genetic alterations underlying intellectual disability, 
clinical practice is being compelled to move to a new paradigm of “genotype-first”, followed 
by a more detailed clinical characterization as more patients with the same alteration are 
discovered. The exception will be cases in which the clinical phenotype is so well defined 
and evident, e.g. in some cases of syndromic intellectual disability, that this alone will give a 
clear indication of the underlying genetic cause. 
Perhaps the biggest challenge of all is implementation - how these technologies will be 
applied to the clinical procedure. In order for these to be applied to clinical genetic 
diagnosis, several practical and ethical issues must be overcome. There is the need for 
national and international regulatory bodies to produce technical guidelines and procedures 
to allow the integration to diagnostics. With regard to massive parallel sequencing, and 
from a technical perspective, these should provide recommendations for sequence depth 
and coverage requirements, quality metrics, and additional validation procedures. The 
creation of extensive databases of genetic variance for healthy and disease individuals must 
also be fostered, as this will be required for correct interpretation of data, specially 
concerning new variants, and must take into account the natural occurring variances found 
in regional or ethnic groups. The ethical challenges brought by these technical 
advancements are perhaps even more controversial. Complete genome data, and even only 
exome data, will contain thorough information unrelated to the disease being tested. These 
may contain the carrier status or indicate the presence of high risk variants regarding other 
diseases. So there must be a responsible management on if, what and how this information 
will be returned to the patients, and on the psychological consequences of having 
knowledge of such data (Sharp, 2011). Other, more practical concerns, regard the ownership, 
storage and access to the data, especially considering future unanticipated applications. 
Another aspect that should be taken into account are cases where no conclusion can be 
drawn at the moment of analysis. Considering the rate at which the biological processes 
underlying intellectual disability are being unravelled, and new intellectual disability or 
modifier genes are being discovered, these negative cases should be kept “on hold” and re-
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evaluated in light of this new flow of information. This will likely require more integration 
between research and diagnostic laboratories to tackle these new evidences. In the years 
ahead of us, we will certainly see massive parallel sequencing acquiring the “first-tier test” 
position in clinical diagnosis.  
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